|
gptkbp:instanceOf
|
gptkb:drug
sympathomimetic drug
|
|
gptkbp:approvedBy
|
1950s
|
|
gptkbp:ATCCode
|
R01AA04
|
|
gptkbp:brand
|
gptkb:Sudafed_PE
gptkb:Neo-Synephrine
|
|
gptkbp:CASNumber
|
61-76-7
|
|
gptkbp:category
|
vasoconstrictor
decongestant
mydriatic
pressor agent
|
|
gptkbp:chemicalFormula
|
phenethylamine derivative
|
|
gptkbp:contraindication
|
gptkb:ventricular_tachycardia
severe hypertension
|
|
gptkbp:discoveredBy
|
gptkb:Smith,_Kline_&_French
|
|
gptkbp:efficacyDebate
|
oral form efficacy questioned for nasal congestion
|
|
gptkbp:eliminationHalfLife
|
2.5 to 3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C9H13NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
phenylephrine
|
|
gptkbp:legalStatus
|
over-the-counter (oral, topical)
prescription (IV)
|
|
gptkbp:mechanismOfAction
|
alpha-1 adrenergic receptor agonist
|
|
gptkbp:meltingPoint
|
143–145 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children under 6 (oral)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
6041
DB00388
|
|
gptkbp:regulates
|
approved
|
|
gptkbp:relatedTo
|
gptkb:pseudoephedrine
epinephrine
|
|
gptkbp:riskFactor
|
anxiety
insomnia
urinary retention
|
|
gptkbp:routeOfAdministration
|
oral
topical
intravenous
|
|
gptkbp:sideEffect
|
headache
hypertension
reflex bradycardia
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:UNII
|
1WS297W6MV
|
|
gptkbp:usedFor
|
nasal congestion
hypotension
mydriasis induction
|
|
gptkbp:bfsParent
|
gptkb:Robitussin
gptkb:Dimetapp
gptkb:Preparation_H
|
|
gptkbp:bfsLayer
|
6
|